WOCKHARDT
|
WOCKHARDT Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 13.15 | -2.90 | -30.06 | -38.82 | -16.94 |
| CEPS(Rs) | 26.30 | 9.88 | -16.17 | -25.69 | -2.22 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 304.14 | 268.02 | 217.27 | 231.81 | 266.04 |
| Tax Rate(%) | 16.39 | -256.25 | -12.38 | 0.48 | 32.12 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.13 | 10.16 | 1.08 | 2.36 | 5.81 |
| EBIT Margin(%) | 11.62 | 6.15 | -3.19 | -7.54 | -2.18 |
| Pre Tax Margin(%) | 6.13 | -0.41 | -11.65 | -14.60 | -8.01 |
| PAT Margin (%) | 5.13 | -1.47 | -13.09 | -14.53 | -5.44 |
| Cash Profit Margin (%) | 10.98 | 4.14 | -6.91 | -8.66 | -0.62 |
| Performance Ratios | |||||
| ROA(%) | 2.53 | -0.78 | -6.67 | -8.42 | -3.71 |
| ROE(%) | 4.29 | -1.48 | -14.12 | -17.32 | -7.77 |
| ROCE(%) | 6.79 | 4.07 | -2.15 | -5.88 | -1.96 |
| Asset Turnover(x) | 0.49 | 0.53 | 0.51 | 0.58 | 0.68 |
| Sales/Fixed Asset(x) | 0.65 | 0.67 | 0.63 | 0.73 | 0.88 |
| Working Capital/Sales(x) | 3.94 | 9.14 | -5.02 | -2.81 | -6.73 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.54 | 1.49 | 1.58 | 1.37 | 1.14 |
| Receivable days | 58.75 | 60.36 | 71.63 | 73.25 | 65.29 |
| Inventory Days | 75.82 | 64.42 | 65.71 | 60.95 | 55.76 |
| Payable days | 186.21 | 218.94 | 255.81 | 293.71 | 232.91 |
| Valuation Parameters | |||||
| PER(x) | 89.54 | - | - | - | - |
| PCE(x) | 44.77 | 144.15 | -36.09 | -5.99 | -118.71 |
| Price/Book(x) | 3.87 | 5.31 | 2.69 | 0.66 | 0.99 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 6.21 | 8.21 | 3.78 | 1.50 | 1.63 |
| EV/Core EBITDA(x) | 27.45 | 54.36 | 86.64 | 17.85 | 16.52 |
| EV/EBIT(x) | 46.44 | 103.92 | -91.91 | -12.36 | -46.92 |
| EV/CE(x) | 2.96 | 3.98 | 1.93 | 0.76 | 0.69 |
| M Cap / Sales | 5.65 | 7.66 | 3.21 | 0.84 | 1.18 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 11.99 | 7.65 | 5.55 | -17.93 | 19.28 |
| Core EBITDA Growth(%) | 67.69 | 272.95 | -45.29 | -29.87 | 360.87 |
| EBIT Growth(%) | 89.50 | 306.96 | 64.29 | -187.50 | 64.89 |
| PAT Growth(%) | 449.12 | 87.92 | 23.99 | -122.58 | 6.06 |
| EPS Growth(%) | 553.20 | 90.35 | 22.55 | -129.10 | -127.17 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.43 | 0.43 | 0.63 | 0.57 | 0.49 |
| Current Ratio(x) | 1.61 | 1.21 | 0.74 | 0.56 | 0.76 |
| Quick Ratio(x) | 1.06 | 0.85 | 0.51 | 0.37 | 0.52 |
| Interest Cover(x) | 2.12 | 0.94 | -0.38 | -1.07 | -0.37 |
| Total Debt/Mcap(x) | 0.11 | 0.08 | 0.24 | 0.85 | 0.49 |
Compare Financial Ratios of peers of WOCKHARDT
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WOCKHARDT | ₹30,048.7 Cr | -2.8% | -8% | 2.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹468,842.0 Cr | 1.1% | 4.6% | 14.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹193,860.0 Cr | 0.6% | 8.3% | 8.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹192,687.0 Cr | 6.3% | 12.2% | 45.5% | Stock Analytics | |
| CIPLA | ₹112,593.0 Cr | -1.7% | -2.8% | -4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,364.9 Cr | -3.7% | -10.4% | -6% | Stock Analytics | |
WOCKHARDT Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WOCKHARDT | -2.8% |
-8% |
2.3% |
| SENSEX | -1% |
-0.9% |
-7.5% |
You may also like the below Video Courses
